Sleep apnea is a major risk factor for cardiovascular and cerebrovascular disease, according to Airfinity, a disease forecasting company. In its weekly Obesity Market Intelligence newsletter, Airfinity projected there are 23.2 million U.S. adults living with obesity and sleep apnea. By 2040, that prevalence is expected to increase to 30.1 million adults.
Wegovy, a popular weight loss drug, could curb the nation’s market of continuous positive airway pressure machines by 11% within six years. This decrease would be from $14.2 billion to $12.6 billion — and stronger anti-obesity drug candidates could shrink this market by nearly twice as much, Airfinity said.
The company outlined two other scenarios. By 2025, Wegovy can prevent between 2 million and 3 million cases of sleep apnea, and between 2.2 million and 3.3 million can be averted by 2027.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
